New MRI dye tested against standard for kidney scans
NCT ID NCT07040865
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a newer MRI contrast agent, gadopiclenol, with the standard agent, gadobutrol, for imaging the kidneys and adrenal glands. About 104 adults with incidental findings on scans will receive one of the two agents during a single MRI session. The goal is to see if the newer agent provides equally clear images, which could give doctors another option for these types of scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gadopiclenol (Vueway) and gadobutrol (Gadovist) contrast agents
What this could lead to
If gadopiclenol works as well as the standard contrast agent, it could offer a safe and effective alternative for MRI scans of the kidneys and adrenal glands.
What could go wrong
This is a small, early-phase trial (104 people) comparing two similar agents. It may not show a clear difference, and results may not apply to all patients or imaging types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUSPECT RENAL AND ADRENAL IMAGING FINDINGS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Diagnostic, Interventional and Pediatric Radiology Inselspital, University of Bern
RECRUITINGBern, 3010, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact